ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vandria has launched with $20.6 million in series A funding to develop small-molecule mitophagy inducers. Vandia, which spun out of the Swiss firm Amazentis, will develop compounds to treat age-related and chronic muscle, lung, and liver diseases. The new firm already has a lead candidate, VNA-318, for improving memory and learning; it will enter clinical trials this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter